Two hundred million protein shapes, one Nobel Prize, and still zero A I drugs approved.

Run time: 6:32

In today's episode:

1. AlphaFold two hit ~90/100 accuracy at CASP14 (2020)
2. Database now covers 214M+ protein sequences, 3M+ users
3. 2024 Nobel Prize: Hassabis, Jumper (AlphaFold) + Baker (design)
4. AlphaFold3 predicts drug-protein binding, 58% vs 24% docking
5. Static shapes only — fails on flexible, shape-shifting targets
6. Zero AlphaFold-designed drugs approved; first trials targeted end-2026

TL;DR:

• Real, at the research layer: AlphaFold solved a 50-year protein-shape problem (peer-reviewed, Nobel-confirmed) and put 214M+ free structures in front of 3M+ scientists in ~190 countries — it changed how medical research begins.
• Not yet, at the clinic: No AlphaFold-designed drug is approved or, as of spring 2026, even dosed in a patient; the models predict one static shape and stumble on the flexible drug targets that matter most.
• The milestone to watch: Isomorphic Labs (DeepMind spinout, $2.1B Series B) targets its first human cancer trials by end-2026 — that first-dose event, not the Nobel, is where "changed medicine" gets tested against outcome evidence.

Sources cited:

• Nature 2021, Jumper et al.
• Nucleic Acids Research 2024, Varadi et al.
• Nature 2024, Abramson et al.
• EMBL-EBI resource update
• PMC 2025, anti-schistosomal docking pipeline
• bioRxiv 2025, AlphaFold3 in Drug Discovery: capabilities & limitations
• Isomorphic Labs, $2.1B Series B (May 2026)
• NobelPrize.org, Chemistry 2024

Subscribe: YouTube

medAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.